Compare Li Auto Inc (LI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Mesoblast Limited — how do they compare? Li Auto Inc trades at $11.54 (market cap $10.71B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Li Auto Inc is far larger — about 6.1× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 1,781,143). Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and Mesoblast Limited for 15 Days on average.
| LI | MESO | |
|---|---|---|
Market Cap | $10.71B | $1.75B |
Volume | 1,781,143 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.13 | $20.96 |
52-Week Low | $10.69 | $13.19 |
Typical Hold Time | 101 Days | 15 Days |
Enterprise Value | $139.58M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $10.90, down 0.82% and near 52-week lows, reflecting bearish technical signals and recent earnings misses. The company reported declining revenue ($112.31B in 2025) and negative net income margins (-4.4%), though valuation metrics like P/S (0.73) appear attractive. Recent news highlights delivery moderation and new model launches (Li i9, Li MEGA) amid intense EV competition.
The stock faces near-term headwinds from cash burn and competitive pressures, but analyst consensus remains cautiously optimistic with a $15.18 price target. Key risks include execution challenges in global expansion and margin recovery, while potential upside hinges on successful product cycles and cost management improvements.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
